Molecular Genetic Cardiomyopathy gene panel-NGS
Also Known As
Test Parameters Included
- Panel of cardiomyopathy-associated genes analyzed by Next-Generation Sequencing (NGS)
- Genes typically include MYH7, MYBPC3, TNNT2, TNNI3, TPM1, TTN, PLN, LMNA, FLNC, RBM20, and others relevant to hypertrophic, dilated, and arrhythmogenic cardiomyopathies
- Pathologist Molecular Genetics Remark - variant classification (pathogenic, likely pathogenic, VUS, benign) mapped against ACMG/AMP guidelines
Department
Methodology
Sample Required
Preparation
Schedule Report
35 Days
Emergency Report
Yes
Frequently Asked Questions
What is a Molecular Genetic Cardiomyopathy gene panel-NGS?
It is a next-generation sequencing test that analyzes multiple genes associated with inherited cardiomyopathies such as hypertrophic, dilated, and arrhythmogenic cardiomyopathy to identify pathogenic variants.
Who should undergo this genetic test?
It is recommended for patients diagnosed with or at risk of cardiomyopathy, family members of individuals with known genetic cardiomyopathy, and those with unexplained left ventricular hypertrophy or sudden cardiac death in the family.
Is fasting required for this test?
No, fasting is not required. The test uses whole blood collected in an EDTA tube.
How long does it take to get results?
Turnaround time is typically 7–14 working days, depending on the laboratory's NGS workflow and variant confirmation steps.
What do the results mean?
Results may identify a pathogenic or likely pathogenic variant, a variant of uncertain significance (VUS), or no variant. A positive result guides clinical management, family screening, and genetic counseling.
Can medications affect the test results?
No, medications do not affect genetic results since the test analyzes DNA sequence, not biochemical markers.
Test Description
Test Code
MOG78
- High-end laboratory & medical equipment.
- Outstanding doctor team.
- Personalized care & high-quality service.
- Tailormade health screening packages.